(133 days)
Not Found
No
The summary describes a standard infusion pump with a micro-dosing mechanism and acoustic volume sensor feedback. There is no mention of AI, ML, or any related concepts in the device description, intended use, or performance studies.
Yes
The device is intended for the continuous subcutaneous delivery of Remodulin® to treat pulmonary arterial hypertension (PAH), which is a therapeutic application.
No
Explanation: The device description states it is a "wearable infusion pump designed to deliver Remodulin® for the treatment of pulmonary arterial hypertension (PAH)." This indicates it is a therapeutic device, not one used for diagnosis.
No
The device description explicitly lists multiple hardware components including a wearable pump assembly, remote interface, filling and priming aid, accessories (rechargeable batteries, battery charger, charging cable, power adapter), and a disposable single-use cassette. Performance studies also include testing of hardware aspects like electrical safety and EMC.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the delivery of a drug (Remodulin) to a patient. IVDs are used to examine specimens from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description: The description details a pump system for drug infusion, not a device for analyzing biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological specimens, detecting analytes, or providing diagnostic information based on in vitro testing.
The device is clearly a drug delivery system, which falls under a different category of medical devices than IVDs.
N/A
Intended Use / Indications for Use
The Remunity® Pump for Remodulin® (treprosimil) Injection (the Remunity System) is intended for continuous subcutaneous delivery of Remodulin (treprostinil) Injection for use in adults (greater than 22 years old).
Product codes
QJY
Device Description
The Remunity Subcutaneous Delivery System for Remodulin® (Remunity System) is a wearable infusion pump designed to deliver Remodulin® for the treatment of pulmonary arterial hypertension (PAH). It is intended for continuous subcutaneous delivery of FDA-approved Remodulin® (treprostinil) (hereinafter referred to as 'Remodulin®' or 'Remodulin® (treprostinil)'), NDA 021272. The Remunity System consists of several components: a wearable pump assembly, a remote interface, a filling and priming aid, and accessories (e.g., rechargeable batteries, battery charger, charging cable, power adapter). A commercially available subcutaneous infusion set is connected to the pump assembly via a standard luer connector for the delivery of Remodulin® from the Remunity System to the patient.
The pump assembly is composed of a reusable pump and a disposable single-use cassette with a pharmacy-filled or user-filled drug reservoir, which infuses Remodulin® subcutaneously into the patient based on an individualized programmed rate. Each disposable cassette may be used for up to 72 hours after attachment to the pump. The Remunity System utilizes a micro-dosing pump mechanism supplemented with acoustic volume sensor feedback to ensure delivery accuracy.
The device is prescription use only.
The modified device utilizes a touchscreen remote controller.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
subcutaneous
Indicated Patient Age Range
adults (greater than 22 years old)
Intended User / Care Setting
In professional healthcare facilities and home environments
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing was conducted in order to verify and validate the subject device remote interface for its intended use, and to establish substantial equivalence to the respective predicate device remote interface in terms of safety and effectiveness. The FDA Guidance Document, Infusion Pumps Total Product Life Cycle, issued December 2, 2014 was followed.
Device Performance: The following functional areas, specific to the remote interface, were evaluated: Touchscreen Remote Reliability, Touchscreen Remote Functionality, Wireless Communication.
Software and Cybersecurity: The subject device is considered to require an “Enhanced Documentation Level” per the 2023 FDA guidance document. Software and Cybersecurity testing was conducted per ANSI AAMI IEC 62304:2006/A1:2016 and the following FDA Guidance Documents:
• Content of Premarket Submissions for Device Software Functions, issued June 14, 2023
• Off-The-Shelf Software Use in Medical Devices, issued September 27, 2019
• Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, issued September 27, 2023
• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, issued April 8, 2020
• Cybersecurity in Medical Devices: Refuse to Accept Policy for Cyber Devices and Related Systems Under Section 524B of the FD&C Act, issued March 30, 2023
Human Factors: The human factors evaluation followed the FDA Guidance Document, Applying Human Factors and Usability Engineering to Medical Devices, issued February 3, 2016, and the following standards:
• IEC 60601-1-6:2020
• ANSI AAMI IEC 62366-1:2015+A1:2020
Electrical Safety: Per IEC 60601-1:2020
EMC: Per IEC 60601-1-2:2020
Alarms: Per IEC 60601-1-8:2020
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5725 Infusion pump.
(a)
Identification. An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
June 12, 2024
Deka Research and Development Paul Smolenski Regulatory Affairs 340 Commercial Street Manchester, New Hampshire 03101
Re: K240256
Trade/Device Name: Remunity System Regulation Number: 21 CFR 880.5725 Regulation Name: Infusion pump Regulatory Class: Class II Product Code: QJY Dated: Mav 9, 2024 Received: May 10, 2024
Dear Paul Smolenski:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
2
Sincerely,
Jake K. Lindstrom -S
Jake Lindstrom, Ph.D. Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K240256
Device Name Remunity System
Indications for Use (Describe)
The Remunity® Pump for Remodulin® (treprosimil) Injection (the Remunity System) is intended for continuous subcutaneous delivery of Remodulin (treprostinil) Injection for use in adults (greater than 22 years old).
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/0 description: The image shows the word "DEKA" in a bold, sans-serif font. The letters are all capitalized and black. The "K" is stylized with an arrow shape pointing to the left.
510(k) Summary
This 510(k) Summary of Safety and Effectiveness information is prepared in accordance with the requirements of 21 CFR Part 807.92.
Submitter Information
| 510(k) Sponsor | DEKA Research & Development
340 Commercial Street
Manchester, NH 03101 |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person(s) | Paul Smolenski (primary), Lauren Blake (secondary)
Regulatory Affairs
Phone: (603) 669-5139
Fax: (603) 624-0573
psmolenski@dekaresearch.com, lblake@dekaresearch.com |
Date Prepared January 30, 2024
Proposed Device(s)
| Common/Usual Name: | Infusion Pump |
|---|---|
| Trade/Proprietary Name: | Remunity Subcutaneous Delivery System for Remodulin® |
| Classification Name: | Infusion pump, drug specific, pharmacy-filled |
| Device Classification: | 880.5725 |
| Product Code: | QJY |
| Class: | II |
| Device Panel: | General Hospital |
Predicate Device(s)
The predicate device is the Remunity Subcutaneous Delivery System for Remodulin®, which was previously cleared under premarket application K202690 on December 30, 2020.
Device Description
The Remunity Subcutaneous Delivery System for Remodulin® (Remunity System) is a wearable infusion pump designed to deliver Remodulin® for the treatment of pulmonary arterial hypertension (PAH). It is intended for continuous subcutaneous delivery of FDA-approved
5
Image /page/5/Picture/0 description: The image shows the word "DEKA" in a bold, sans-serif font. The letters are all capitalized and black. The "K" in the word is stylized with an arrow shape in the middle.
Remodulin® (treprostinil) (hereinafter referred to as 'Remodulin®' or 'Remodulin® (treprostinil)'), NDA 021272. The Remunity System consists of several components: a wearable pump assembly, a remote interface, a filling and priming aid, and accessories (e.g., rechargeable batteries, battery charger, charging cable, power adapter). A commercially available subcutaneous infusion set is connected to the pump assembly via a standard luer connector for the delivery of Remodulin® from the Remunity System to the patient.
The pump assembly is composed of a reusable pump and a disposable single-use cassette with a pharmacy-filled or user-filled drug reservoir, which infuses Remodulin® subcutaneously into the patient based on an individualized programmed rate. Each disposable cassette may be used for up to 72 hours after attachment to the pump. The Remunity System utilizes a micro-dosing pump mechanism supplemented with acoustic volume sensor feedback to ensure delivery accuracy.
The device is prescription use only.
The modified device utilizes a touchscreen remote controller.
Indications for Use
The Remunity® Pump for Remodulin® (treprostinil) Injection (the Remunity System) is intended for continuous subcutaneous delivery of Remodulin (treprostinil) Injection for use in adults (greater than 22 years old).
Substantial Equivalence Discussion
Intended Use Comparison
| Characteristic | Predicate Device - Remunity
System (K202690) | Subject Device – Remunity
System |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications for Use | The Remunity Subcutaneous
Infusion System (the Remunity
System) is intended for
continuous subcutaneous
delivery of Remodulin®
(treprostinil) Injection for use in
adults (greater than 22 years of
age). | The Remunity® Pump for
Remodulin® (treprostinil)
Injection (the Remunity System)
is intended for continuous
subcutaneous delivery of
Remodulin (treprostinil)
Injection for use in adults
(greater than 22 years old). |
The tables below includes a matrix of the intended use between the subject device and the predicate device.
6
Image /page/6/Picture/0 description: The image shows the word "DEKA" in a bold, sans-serif font. The letters are all capitalized and black. The letters are closely spaced together, and the overall appearance is modern and industrial.
| Characteristic | Predicate Device – Remunity
System (K202690) | Subject Device – Remunity
System |
|--------------------------------------------------|-------------------------------------------------------------------|-------------------------------------|
| Prescription Use or
Over the Counter
(OTC) | Prescription | No change |
| Intended Patient
Population | Greater than 22 years of age | No change |
| Patient Environment | On-body wearable ambulatory
pump | No change |
| Environment of Use | In professional healthcare
facilities and home
environments | No change |
The intended use remains unchanged in the subject device with respect to the predicate device (K202690). The Indications for Use have been updated to reflect the current branding for the device. This update does not affect the intended patient population or environment of use.
Technological Characteristic Comparison
The table below compares the characteristics of the predicate and subject devices, and includes an assessment of the differences and why these differences do not introduce new or different questions of safety and effectiveness.
| Characteristic | Predicate Device –
Remunity System
(K202690) | Subject Device –
Remunity System | Equivalence |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Delivery
Method | Microprocessor
controlled micro-
dosing pump
mechanism
supplemented with
acoustic volume sensor
(AVS) feedback for
monitoring delivery
accuracy | Same | N/A |
| Delivery type | Subcutaneous infusion | Same | N/A |
| Dimensions | 6 cm x 6 cm x 2 cm
(2.4 in x 2.4 in x 0.4 in) | Same | N/A |
| Weight | 50 g (1.76 oz.) | Same | N/A |
| Basal Delivery
Rate Range | 16 μL/hr – 225 μL/hr,
with increments of 1
μL/hr | Same | N/A |
| Basal Accuracy | +6% | Same | N/A |
| Characteristic | Predicate Device –
Remunity System
(K202690) | Subject Device -
Remunity System | Equivalence |
| Bolus Volume
after Occlusion
Release | ) | Same | N/A |
11
Image /page/11/Picture/0 description: The image shows the word "DEKA" in a bold, sans-serif font. The letters are all capitalized and black. The "K" is stylized with a sharp, arrow-like shape pointing to the left. The background is white.
| Characteristic | Predicate Device –
Remunity System
(K202690) | Subject Device –
Remunity System | Equivalence |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------|
| Material
Biocompatibility | Cassette fluid path:
Polycarbonate (PC),
Bromobutyl, SEBS,
polyurethane | Same | N/A |
| | Pump: ABS, PC,
Aluminum | | |
| | Cartridge: PC, Acrylic,
polyurethane | | |
| | Filling Aid: PC-ABS | | |
| | Cap (Pharmacy-fill):
ABS | | |
| | | | |
| Pharmacy-fill
End-user
Packaging | Aseptically filled
cassette with female
luer lock fluid path
closure, placed in
plastic clamshell tray
and sealed in foil pouch | Same | N/A |
| Priming Method | Manually primed by
user before Cassette
attachment to the Pump | Same | N/A |
Performance Data
Performance testing was conducted in order to verify and validate the subject device remote interface for its intended use, and to establish substantial equivalence to the respective predicate device remote interface in terms of safety and effectiveness. The FDA Guidance Document, Infusion Pumps Total Product Life Cycle, issued December 2, 2014 was followed.
| Device
Performance | The following functional areas, specific to the remote interface, were evaluated:
Touchscreen Remote Reliability Touchscreen Remote Functionality Wireless Communication |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Software and
Cybersecurity | The subject device is considered to require an “Enhanced Documentation Level” per the 2023 FDA guidance document. |
12
Image /page/12/Picture/0 description: The image shows the word "DEKA" in a bold, sans-serif font. The letters are all capitalized and black. The letters are stylized with rounded corners and a slightly futuristic look. The "K" is designed with an arrow-like shape pointing to the left.
| | Software and Cybersecurity testing was conducted per ANSI AAMI IEC
62304:2006/A1:2016 and the following FDA Guidance Documents: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | • Content of Premarket Submissions for Device Software Functions,
issued June 14, 2023 |
| | • Off-The-Shelf Software Use in Medical Devices, issued September 27,
2019 |
| | • Content of Premarket Submissions for Management of Cybersecurity
in Medical Devices, issued September 27, 2023 |
| | • Cybersecurity in Medical Devices: Quality System Considerations and
Content of Premarket Submissions, issued April 8, 2020 |
| | • Cybersecurity in Medical Devices: Refuse to Accept Policy for Cyber
Devices and Related Systems Under Section 524B of the FD&C Act,
issued March 30, 2023 |
| Human Factors | The human factors evaluation followed the FDA Guidance Document,
Applying Human Factors and Usability Engineering to Medical Devices,
issued February 3, 2016, and the following standards: |
| | • IEC 60601-1-6:2020 |
| | • ANSI AAMI IEC 62366-1:2015+A1:2020 |
| Electrical Safety | Per IEC 60601-1:2020 |
| EMC | Per IEC 60601-1-2:2020 |
| Alarms | Per IEC 60601-1-8:2020 |
Animal and Clinical Studies
No animal study or clinical trial data was obtained in support of this premarket submission.
Design Control
The Remunity System was specified and developed by DEKA. DEKA complies with the FDA Quality System Regulation as specified in 21 CFR 820, as well as to ISO 13485:2016.
Conclusion
The differences between the predicate and the subject device do not raise any new or different questions of safety or effectiveness. The Remunity Subcutaneous Delivery System for Remodulin® is substantially equivalent to the Remunity Subcutaneous Delivery System for Remodulin® cleared under K202690 with respect to the indications for use, target populations, treatment method, and technological characteristics.